Development of a conditional inducible Huntington’s disease murine model to study complex pathogenic mechanisms

开发条件诱导亨廷顿病小鼠模型以研究复杂的致病机制

• 批准号: 10352824
• 负责人: Mark F Mehler
• 金额: $ 16.8万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10352824
• 关键词: Adult; Affect; Alleles; Anxiety; Bacterial Artificial Chromosomes; Biological; Brain; Brain region; CAG repeat; Cells; Characteristics; Clustered Regularly Interspaced Short Palindromic Repeats; Code; Complex; Corpus striatum structure; DNA cassette; Development; Disease; Distant; Engineering; Event; Excision; Exons; Functional disorder; Gait; Gene Proteins; Genes; Genetic; Genetic Models; Genetic Recombination; Genomics; Goals; Human; Huntington Disease; Huntington gene; Immunohistochemistry; Impairment; Individual; Inflammatory Response; Injections; Intervention; Introns; Investigation; Length; Life; Liver Dysfunction; Location; LoxP-flanked allele; Mediating; Mental Depression; Metabolic; Mission; Modeling; Molecular Disease; Motor; Mus; Mutation; Nervous system structure; Neurodegenerative Disorders; Neurologic; Neurologic Deficit; Neurosecretory Systems; Organ; Pathogenesis; Pathogenicity; Pattern; Peripheral; Physiological; Population; Procedures; Process; Proteins; Public Health; Quantitative Reverse Transcriptase PCR; Regulatory Element; Research; Research Design; Single-Gene Defect; Skeletal Muscle; System; Tamoxifen; Techniques; Therapeutic Intervention; Time; Tissues; Transcript; Transgenes; Transgenic Organisms; Trinucleotide Repeat Expansion; United States National Institutes of Health; Validation; Western Blotting; Yang; base; behavior test; body system; cell type; combinatorial; design; disease phenotype; in vivo; innovation; interest; loss of function; motor deficit; mouse model; mutant; nervous system disorder; neurocognitive disorder; neurodevelopment; neuropsychiatric disorder; novel; offspring; pleiotropism; polyglutamine; postnatal; precision medicine; promoter; relating to nervous system; tool; trait; transgene expression; zygote

Huntington’s disease (HD) is caused by a single gene defect consisting of an aberrant trinucleotide repeat expansion in Huntingtin (HTT). This genetic defect gives rise to a broad array of pathophysiological alterations leading to a multi-system disease whose most characteristic traits are those resulting from its neurological alterations: neuropsychiatric disorders, motor deficits and striatal degeneration. However, no less important are those disease traits resulting from impairments affecting other organ, tissue and cellular systems, including aberrant inflammatory responses, skeletal muscle dysfunction, metabolic alterations, and liver dysfunction. Given this systemic involvement, these impairments likely synergize with neurological deficits, further altering their disease course. To further complicate the study of HD pathogenesis, recent investigations have shown that pathogenic alterations also result from asynchronous events taking place during early neural development, postnatal maturation as well as throughout adult life. This complex interplay, involving multiple cellular alterations, time-dependent processes and their concerted interactions, has made it particularly challenging to elucidate primary mechanistic events and processes and, as a corollary, to promote the design of precision medicine interventions. To effectively dissect specific primary pathophysiological mechanisms, it is necessary to employ a genetic tool with the ability to conditionally induce the full-length mutant gene in HD-targeted cells at the relevant times and places underlying disease pathogenesis. To accomplish this goal, we have created a novel genetic model whose expression of the human full-length mutant HTT transgene is abrogated by the presence of a loxP floxed STOP cassette within HTT intron 1, the iBACHD strain. The overall goal of this R03 application is to genetically characterize the iBACHD strain, and to validate its use for better modeling of HD in vivo. The characterization and validation of the iBACHD model will be achieved through three Specific Aims: (1) the characterization of transgene integration in term of copy number and genomic location; (2) the characterization of STOP cassette functional integrity and the pattern of expression of mutant human HTT after excisional recombination of the STOP cassette; and (3) ability of the iBACHD model to recapitulate the main hallmarks of HD: neuropsychiatric abnormalities, motoric deficits and striatal degeneration. These studies are significant as they will fill a critical gap in our experimental arsenal to dissect individual mechanisms of a multi- system disorder. Our studies will yield a highly innovative tool that would result in a departure from the status quo of mechanistic studies based on mouse models with less versatile expression of the pathogenic gene and protein product.

亨廷顿病(HD)是由一个由三核苷酸重复序列组成的单基因缺陷引起的 在亨廷顿的扩张(HTT)。这种遗传缺陷引起了一系列广泛的病理生理变化。 导致一种多系统疾病，其最具特征的特征是由其神经系统引起的 改变：神经精神障碍、运动障碍和纹状体变性。然而，同样重要的是 这些疾病特征是由影响其他器官、组织和细胞系统的损伤引起的，包括 异常炎症反应、骨骼肌功能障碍、代谢改变和肝功能障碍。 考虑到这种全身性参与，这些损伤可能与神经缺陷协同作用，进一步改变 他们的病程。为了使HD发病机制的研究进一步复杂化，最近的研究表明 致病改变也是在早期神经发育过程中发生的异步事件造成的， 出生后成熟，以及整个成年生活。这种复杂的相互作用，涉及多个细胞 变化，依赖于时间的过程及其协调的交互，使得它特别具有挑战性 阐明主要的机械事件和过程，并作为推论，促进精度的设计 药物干预。为了有效地剖析特定的主要病理生理机制，有必要 使用一种能够有条件地在HD靶向细胞中诱导全长突变基因的遗传工具 相关的时间和地点的潜在疾病的发病机制。为了实现这一目标，我们创建了一个 一种新的遗传模型，其表达的人全长突变型HTT转基因被 IBACHD菌株HTT内含子1中存在loxP有牙线状的止血盒。这款R03的总体目标 应用是对iBACHD毒株的遗传学特征进行鉴定，并验证其在更好地模拟HD的应用 活着。IBACHD模型的特性和验证将通过三个具体目标实现： (1)从拷贝数和基因组位置来表征转基因整合；(2) 阻断盒功能完整性的鉴定及突变型人HTT基因表达模式的研究 截断盒式磁带的切除重组；以及(3)iBACHD模型概括主要 HD的特征：神经精神异常、运动障碍和纹状体变性。这些研究是 尽管它们将填补我们实验武器库中的一个关键空白，以剖析多个 系统紊乱。我们的研究将产生一种高度创新的工具，这将导致偏离现状 基于致病基因和致病基因表达不多的小鼠模型的机制研究现状 蛋白质产品。